United States-based Bristol-Myers Squibb has named Cancer Research UK's Karen Vousden as its director effective January 2017, it is reported today.
Presently, Vousden is the chief scientist at Cancer Research UK and is serving as group leader at the Francis Crick Institute in London and will also sit the pharma firm's Science and Technology Committee. She has more than 30 years' experience in cancer research and her earlier roles included director of the Beatson Institute for Cancer Research and leadership positions at the US National Cancer Institute.
Giovanni Caforio, BMS' chairman and chief executive officer, said, 'Karen is a world class cancer researcher and a highly accomplished leader in her field. Her understanding of cancer biology and immunology research will bring valuable insights to advancing our strategy and strong pipeline in oncology along with our broader pipeline of transformational medicines.'
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
InSysBio agrees new collaborative project with BeOne Medicines
Physiomics secures new modelling contract with Numab Therapeutics
Mabwell reports first patient dosed with 7MW4911 in US trial
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
Avacta secures FDA clearance for second pre|CISION oncology programme
Guardant Health and Merck enter multi-year oncology diagnostics collaboration
Akeso secures NMPA review acceptance for gumokimab in ankylosing spondylitis